

Antisense Oligonucleotide (ASO) Therapeutics
Market

Antisense Oligonucleotide (ASO) Therapeutics
Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031

Request Sample Report


Antisense Oligonucleotide (ASO) Therapeutics Market Size and Growth
The global Antisense Oligonucleotide (ASO) Therapeutics market is projected to experience significant growth due to rising demand for targeted and personalized therapies. Market size is estimated to reach $X billion by 2026, with a CAGR of X%. Increasing prevalence of genetic disorders and advancements in technology are driving market expansion.

Companies Covered (Covid 19 Impact Covered)
◍ Ionis Pharmaceuticals, Inc
◍ Sarpeta Therapeutics Inc.
◍ Biogen Inc
◍ Alnylam Pharmaceuticals, Inc
◍ Antisense Therapeutics Limited
◍ Arrowhead Pharmaceuticals Inc.
◍ Enzon Pharmaceuticals, Inc.
◍ Bio-Path Holdings, Inc.
◍ GlaxoSmithKline PLC
◍ Geron Corporation (Geron)

The competitive landscape of the Antisense Oligonucleotide Therapeutics Market is dominated by companies such as Ionis Pharmaceuticals, Inc, Sarepta Therapeutics Inc., Biogen Inc, Alnylam Pharmaceuticals, Inc, Antisense Therapeutics Limited, Arrowhead Pharmaceuticals Inc., Enzon Pharmaceuticals, Inc., BioPath Holdings, Inc., GlaxoSmithKline PLC, and Geron Corporation. These companies develop, manufacture, and market ASO therapeutics for various therapeutic applications, contributing to the growth of the market.
- Ionis Pharmaceuticals, Inc reported sales revenue of $507 million in 2020.
- Biogen Inc reported sales revenue of $13.4 billion in 2020.
- Alnylam Pharmaceuticals, Inc reported sales revenue of $596 million in 2020. Request


Market Segmentation
By Application
◍ Genetic Disorders
◍ Neurological Disorders
◍ Oncological Disorders
◍ Metabolic Disorders
◍ Ophthalmic Disorders
◍ Others Request
By Product
◍ Pulmonary Delivery
◍ Intravenous Injections
◍ Intradermal Injections
◍ Intraperitoneal Injections
◍ Topical Delivery
◍ Others















